ClinicalTrials.gg
CompletedNCT05142722BROADWAYUpdated Sep 19, 2025Results posted

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

A Phase 3 interventional study of Placebo and Obicetrapib in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 181 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by NewAmsterdam Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.

Enrollment
Largest of 14
2,530 · median 116
Started
2021
with 2 others
Phase 3
3 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
8 of 14
NewAmsterdam Pharma

Among the 14 studies testing TA-8995 in Dyslipidemias, this one has the largest enrollment, is one of 3 that started in 2021, is one of 3 in phase 3, and was the 9th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About TA-8995

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing TA-8995 in Dyslipidemias, or all of them as a file.
02

Study summary

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy

Read the detailed description

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying HeFH and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy. The screening period for this study will take up to 28 days. Afterwards patients will be randomized to placebo or 10 mg obicetrapib for a 365 day treatment period. After the treatment period, patients will have an end of study follow-up visit.

03

Conditions studied

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • Atherosclerotic Cardiovascular Disease

Keywords

  • obicetrapib
  • BROADWAY
  • Cholesteryl ester transfer protein (CETP) inhibitor
  • Heterozygous Familial Hypercholesterolemia (HeFH)
  • Atherosclerotic Cardiovascular Disease (ASCVD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females may be enrolled if all 3 of the following criteria are met:
  • They are not pregnant;
  • They are not breastfeeding; and
  • They do not plan on becoming pregnant during the study;
  • Have underlying heterozygous familial hypercholesterolemia (HeFH) and/or a history of established ASCVD
  • Are on maximally tolerated lipid-modifying therapy as an adjunct to a lipid-lowering diet and other lifestyle modifications, defined as follows:
  • A statin at a maximally tolerated stable dose for at least 8 weeks prior to Screening
  • Atorvastatin 40 and 80 mg; and
  • Rosuvastatin 20 and 40 mg;
  • Ezetimibe with or without maximally tolerated statin for at least 8 weeks prior to Screening
  • Bempedoic acid with a maximally tolerated statin for at least 8 weeks prior to Screening
  • A PCSK-9 targeted therapy alone or in combination with other lipid-modifying therapy for at least 4 stable doses prior to Screening
  • Have a fasting serum LDL-C at Screening as follows:
  • Fasting serum LDL-C ≥ 55 to \< 100 mg/dL (≥1.4 to \<2.6 mmol/L) OR non-HDL-C ≥85 mg/dL (≥2.2 mmol/L) to \< 130 mg/dL (\<3.4 mmol/L) with at least 1 of the following risk enhancers at Screening;
  • Recent MI (> 3 and \< 12 months prior to Randomization);
  • Type 2 diabetes mellitus;
  • Current daily cigarette smoking;
  • Age of > 60 years;
  • High sensitivity C-reactive protein (hsCRP) ≥2.0 mg/L (≥19.0 nmol/L) at Screening or within 6 months prior to Screening
  • Fasting triglycerides (TG) > 150 mg/dL (>1.7 mmol/L);
  • Fasting lipoprotein (a) > 30 mg/dL (>70 nmol/L); and/or
  • Fasting HDL-C \< 40 mg/dL (\<1.0 mmol/L); OR
  • Fasting serum LDL-C ≥ 100 mg/dL (≥2.6 mmol/L) or non-HDL-C ≥130 mg/dL (≥3.4 mmol/L)
  • Fasting triglyceride (TG) \< 500 mg/dL (\<5.7 mmol/L) at Screening; and
  • Have an estimated (eGFR) ≥30 mL/min/1.73m2 at Screening

Exclusion criteria

Exclusion Criteria:

  • class III or IV heart failure or \< 30%;
  • Hospitalized for heart failure within 5 years prior to Screening
  • Major adverse cardiac event (MACE) within 3 months prior to Screening;
  • Uncontrolled severe hypertension, defined as either systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg prior to Randomization;
  • Formal diagnosis of homozygous familial hypercholesterolemia (HoFH);
  • Active liver disease;
  • ≥10% or a fasting glucose ≥270 mg/dL (≥15.0 mmol/L) at Screening;
  • Thyroid-stimulating hormone >1.5 X (ULN) at Screening;
  • Creatine kinase > 3 X upper limit of normal (ULN) at Screening;
  • History of that required surgery (excluding local and wide local excision), radiation therapy, and/or systemic therapy during the 3 years prior to Randomization;
  • Known history of alcohol and/or drug abuse within 5 years prior to Randomization
  • Received treatment with other products or devices within 30 days of Screening or 5 half-lives of the previous investigational product, whichever is longer;
  • Are taking gemfibrozil or have taken gemfibrozil within 30 days of Screening
  • Planned use of other investigational products or devices during the course of the study;
  • Participated in any clinical trial evaluating obicetrapib; or
  • Known allergy or to obicetrapib, placebo, or any of the in obicetrapib or placebo
  • Any condition that, according to the Investigator, could interfere with the conduct of the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,530 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    one placebo tablet once daily

    Drug: Placebo

  • Experimental
    obicetrapib 10mg

    one 10mg obicetrapib tablet once daily

    Drug: Obicetrapib

Interventions

  • DrugPlacebo

    placebo tablet made to resemble active

  • 10mg obicetrapib tablet

06

What researchers measure

Primary outcomes

  1. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]

    LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 84 Days

Secondary outcomes

  1. Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]

    LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[Martin/Hopkins\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \>= 400 mg/dL or LDL-C \<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 180 Days

  2. Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]

    LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 365 Days

  3. Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  4. Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180

    LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

    Time frame: 180 Days

  5. Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365

    LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

    Time frame: 365 Days

  6. Percent Change in Non-HDL-C From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  7. Percent Change in Non-HDL-C From Baseline to Day 180

    LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.

    Time frame: 180 Days

  8. Percent Change in Non-HDL-C From Baseline to Day 365

    LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.

    Time frame: 365 Days

  9. Percent Change in HDL-C From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  10. Percent Change in HDL-C From Baseline to Day 180

    LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.

    Time frame: 180 Days

  11. Percent Change in HDL-C From Baseline to Day 365

    LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.

    Time frame: 365 Days

  12. Percent Change in Lp(a) From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  13. Percent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in Apolipoprotein A1 (ApoA1) in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  14. Percent Change in Total Cholesterol From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  15. Percent Change in Total Cholesterol From Baseline to Day 180

    LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group.

    Time frame: 180 Days

  16. Percent Change in Total Cholesterol From Baseline to Day 365

    LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group.

    Time frame: 365 Days

  17. Percent Change in Triglycerides From Baseline to Day 84

    LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group.

    Time frame: 84 Days

  18. Percent Change in Triglycerides From Baseline to Day 180

    LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group.

    Time frame: 180 Days

  19. Percent Change in Triglycerides From Baseline to Day 365

    LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group.

    Time frame: 365 days

07

Results

Posted Sep 19, 2025

Participant flow

4214 patients were screened: out of 4214, 2530 participants were randomized (2:1) (obicetrapib: placebo): 1686 participants to the obicetrapib 10 mg group and 844 participants to the placebo group

Participant flow — Overall Study
MilestonePlaceboObicetrapib 10mg
Started8441686
Completed7951600
Not completed4986
Withdrew: Lost to follow-up1638
Withdrew: Withdrawal by subject2027
Withdrew: Death1117
Withdrew: Physician decision01
Withdrew: Participant moved away02
Withdrew: Adverse event21

Outcome measures

PrimaryPercent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]

LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]2.70 ± 1.571-29.94 ± 1.104
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 · Least squares (ls) means: -32.65 · 95% CI -35.79 to -29.50
SecondaryPercent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]

LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[Martin/Hopkins\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \>= 400 mg/dL or LDL-C \<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).

Time frame:
180 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]4.68 ± 1.625-29.09 ± 1.176
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 · Least squares (ls) means: -33.78 · 95% CI -37.07 to -30.49
SecondaryPercent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]

LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
365 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]-1.27 ± 1.798-25.25 ± 1.480
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -23.98 · 95% CI -27.87 to -20.09
SecondaryPercent Change in Apolipoprotein B (ApoB) From Baseline to Day 84

LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 841.08 ± 0.911-17.84 ± 0.669
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -18.92 · 95% CI -20.76 to -17.09
SecondaryPercent Change in Apolipoprotein B (ApoB) From Baseline to Day 180

LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

Time frame:
180 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 1802.23 ± 1.033-16.07 ± 0.742
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -18.31 · 95% CI -20.38 to -16.23
SecondaryPercent Change in Apolipoprotein B (ApoB) From Baseline to Day 365

LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

Time frame:
365 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365-1.77 ± 1.165-15.57 ± 0.914
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -13.80 · 95% CI -16.20 to -11.41
SecondaryPercent Change in Non-HDL-C From Baseline to Day 84

LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Non-HDL-C From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Non-HDL-C From Baseline to Day 842.81 ± 1.212-26.64 ± 0.892
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -29.44 · 95% CI -31.89 to -26.99
SecondaryPercent Change in Non-HDL-C From Baseline to Day 180

LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.

Time frame:
180 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Non-HDL-C From Baseline to Day 180
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Non-HDL-C From Baseline to Day 1803.68 ± 1.302-24.63 ± 0.972
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -28.32 · 95% CI -30.94 to -25.69
SecondaryPercent Change in Non-HDL-C From Baseline to Day 365

LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.

Time frame:
365 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Non-HDL-C From Baseline to Day 365
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Non-HDL-C From Baseline to Day 3650.63 ± 1.480-22.38 ± 1.186
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: -23.02 · 95% CI -26.09 to -19.95
SecondaryPercent Change in HDL-C From Baseline to Day 84

LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in HDL-C From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in HDL-C From Baseline to Day 840.61 ± 1.391136.87 ± 1.857
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: 136.26 · 95% CI 132.46 to 140.07
SecondaryPercent Change in HDL-C From Baseline to Day 180

LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.

Time frame:
180 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in HDL-C From Baseline to Day 180
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in HDL-C From Baseline to Day 1801.18 ± 1.897135.61 ± 2.192
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: 134.43 · 95% CI 129.84 to 139.03
SecondaryPercent Change in HDL-C From Baseline to Day 365

LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.

Time frame:
365 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in HDL-C From Baseline to Day 365
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in HDL-C From Baseline to Day 3653.36 ± 1.651125.40 ± 2.193
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = <.0001 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05) · Least squares (ls) means: 122.04 · 95% CI 117.53 to 126.55
SecondaryPercent Change in Lp(a) From Baseline to Day 84

LS mean percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Lp(a) From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Lp(a) From Baseline to Day 8413.65 ± 8.240-0.48 ± 19.855
Statistical analysis
  • Placebo vs Obicetrapib 10mg · ANCOVA · p = 0.4841 (The hierarchical testing procedure would only be conducted if the previous secondary efficacy endpoint reached a statistically significant treatment effect at p-value\<0.05; therefore hierarchical testing was stopped for subsequent secondary endpoints) · Least squares (ls) means: -14.12 · 95% CI -53.68 to 25.44
SecondaryPercent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 84

LS mean percent change from baseline to Day 84 in Apolipoprotein A1 (ApoA1) in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 840.26 ± 0.59743.44 ± 0.686
SecondaryPercent Change in Total Cholesterol From Baseline to Day 84

LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Total Cholesterol From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Total Cholesterol From Baseline to Day 84-0.02 ± 0.75717.66 ± 0.702
SecondaryPercent Change in Total Cholesterol From Baseline to Day 180

LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group.

Time frame:
180 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Total Cholesterol From Baseline to Day 180
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Total Cholesterol From Baseline to Day 1800.85 ± 0.89318.68 ± 0.769
SecondaryPercent Change in Total Cholesterol From Baseline to Day 365

LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group.

Time frame:
365 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Total Cholesterol From Baseline to Day 365
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Total Cholesterol From Baseline to Day 365-0.58 ± 1.03017.96 ± 0.886
SecondaryPercent Change in Triglycerides From Baseline to Day 84

LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Triglycerides From Baseline to Day 84
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Triglycerides From Baseline to Day 847.66 ± 1.814-0.17 ± 1.445
SecondaryPercent Change in Triglycerides From Baseline to Day 180

LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group.

Time frame:
180 Days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Triglycerides From Baseline to Day 180
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Triglycerides From Baseline to Day 1808.22 ± 2.0610.25 ± 1.584
SecondaryPercent Change in Triglycerides From Baseline to Day 365

LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group.

Time frame:
365 days
Reported as:
Least squares mean · percent change from baseline
Percent Change in Triglycerides From Baseline to Day 365
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Triglycerides From Baseline to Day 3656.33 ± 2.1350.60 ± 1.781
Post-hocPercent Change in Lp(a) From Baseline to Day 84 (Hodges-Lehman)

Median percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group.

Time frame:
84 Days
Reported as:
Median · percent change from baseline
Percent Change in Lp(a) From Baseline to Day 84 (Hodges-Lehman)
percent change from baselinePlaceboObicetrapib 10mg
Percent Change in Lp(a) From Baseline to Day 84 (Hodges-Lehman)-0.9 (-15.7 to 13.0)-32.3 (-62.8 to -4.7)

Adverse events

Collected over From first dose of study drug up to Week 54. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo12/843 (1.4%)117/843 (13.9%)241/843 (28.6%)
Obicetrapib 10mg19/1,685 (1.1%)211/1,685 (12.5%)459/1,685 (27.2%)
Most frequent serious events
Showing 10 of 245
Most frequent serious events
EventPlaceboObicetrapib 10mg
Acute myocardial infarctionCardiac disorders10/84317/1685
Angina unstableCardiac disorders8/84317/1685
Myocardial infarctionCardiac disorders7/8433/1685
PneumoniaInfections and infestations6/8439/1685
Coronary artery diseaseCardiac disorders4/8437/1685
Cardiac failureCardiac disorders4/8435/1685
Acute left ventricular failureCardiac disorders4/8432/1685
Angina pectorisCardiac disorders0/8437/1685
Cerebral infarctionNervous system disorders2/8437/1685
Cerebrovascular accidentNervous system disorders1/8437/1685
Most frequent other events
Most frequent other events
EventPlaceboObicetrapib 10mg
COVID-19Infections and infestations48/84381/1685
HypertensionVascular disorders33/84382/1685
Upper respiratory tract infectionInfections and infestations33/84349/1685
HyperglycaemiaMetabolism and nutrition disorders28/84344/1685
ArthralgiaMusculoskeletal and connective tissue disorders24/84338/1685
NasopharyngitisInfections and infestations22/84343/1685
HeadacheNervous system disorders17/84343/1685
Urinary tract infectionInfections and infestations21/84339/1685
DizzinessNervous system disorders15/84340/1685

Baseline characteristics

Baseline Population is defined as all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboObicetrapib 10mgTotal
Mean65.3 ± 9.6165.4 ± 9.9065.4 ± 9.80
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboObicetrapib 10mgTotal
Female280573853
Male56411131677
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboObicetrapib 10mgTotal
Hispanic or Latino4680126
Not Hispanic or Latino79816052403
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboObicetrapib 10mgTotal
American Indian or Alaska Native156
Asian150312462
Native Hawaiian or Other Pacific Islander000
Black or African American39112151
White64712411888
More than one race279
Unknown or Not Reported5914
Baseline Low-Density Lipoprotein Cholesterol (LDL-C)
Baseline Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL)PlaceboObicetrapib 10mgTotal
Mean98.4 ± 37.9498.1 ± 37.0598.25 ± 37.5
08

Study locations

181 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Synexus Clinical Research US, Inc. / Simon Williamson Clinic, PC
    Birmingham, Alabama 35211, United States
  • The Center for Clinical Trials, Inc
    Saraland, Alabama 36571, United States
  • Syed Research Consultants, LLC
    Sheffield, Alabama 35660, United States
  • Clinical Research Institute of Arizona, LLC
    Sun City West, Arizona 85375, United States
  • Synexus Clinical Research US, Inc. / Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • American Institute of Research
    Beverly Hills, California 90211, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Synexus Clinical Research US, Inc.
    Vista, California 92083, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Pioneer Clinical Studies
    Ft. Pierce, Florida 34950, United States
  • New Generation of Medical Research
    Hialeah, Florida 33016, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32204, United States
  • East Coast Institute for Research, LLC - Jacksonville University Blvd
    Jacksonville, Florida 32216, United States
  • East Coast Institute for Research- Lake City
    Lake City, Florida 32055, United States
  • ClinCloud LLC
    Maitland, Florida 32751, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33125, United States
  • Kendall South Medical Center, Inc.
    Miami, Florida 33185, United States
  • Advanced Research Institute Inc
    New Port Richey, Florida 34653, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • East Coast Institute for Research
    Saint Augustine, Florida 32086, United States
  • Synexus Clinical Research US, Inc.
    The Villages, Florida 32162, United States
  • Synexus Clinical Research US, Inc.
    Atlanta, Georgia 30328, United States
  • East Coast Institute for Research - Canton
    Canton, Georgia 30114, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • East Coast Institute for Research, LLC
    Macon, Georgia 31210, United States
  • Alta Pharmaceutical Research Center
    Peachtree Corners, Georgia 30092, United States
  • SouthCoast Health
    Savannah, Georgia 31406, United States
  • Biofortis, Inc
    Addison, Illinois 60101, United States
  • Evanston Premier Healthcare Research LLC
    Skokie, Illinois 60077, United States
  • Synexus Clinical Research US, Inc.
    Evansville, Indiana 47714, United States
  • Midwest Institute for Clinical Research
    Indianapolis, Indiana 46260, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Tandem Clinical Research GI - Metairie
    Metairie, Louisiana 70006, United States
  • Grace Research, LLC
    Shreveport, Louisiana 71105, United States
  • Southern Clinical Research, LLC
    Zachary, Louisiana 70791, United States
  • Northern Light Cardiology
    Bangor, Maine 04401, United States
  • Privia Medical Group, LLC
    Silver Spring, Maryland 20901, United States
  • Oakland Medical Research
    Troy, Michigan 48085, United States
  • Arcturus Healthcare, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Inspira Medical Centers dba Internal Medicine Associates, P.A.
    Bridgeton, New Jersey 08302, United States
  • Mid Hudson Medical Research
    New Windsor, New York 12553, United States
  • Synexus Clinical Research US, Inc.
    New York, New York 10017, United States
  • Tandem Clinical Research GI, LLC
    New York, New York 10033, United States
  • Chear Center LLC
    The Bronx, New York 10455, United States
  • Diabetes and Endocrinology Consultants, P.C.
    Morehead City, North Carolina 28557, United States
  • Lillestol Research, LLC
    Fargo, North Dakota 58104, United States
  • Summit Research Group, LLC
    Stow, Ohio 44224, United States
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Cardiovascular Research of Knoxville, LLC
    Powell, Tennessee 37849, United States
  • Amarillo Heart Clinical Research Institute, Inc
    Amarillo, Texas 79106, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Apex Mobile Clinical Research
    Bellaire, Texas 77401, United States
  • Javara Inc.
    Conroe, Texas 77384, United States
  • Prime Revival Research Institute, LLC
    Coppell, Texas 75019, United States
  • Thyroid, Endocrinology & Diabetes, PA
    Dallas, Texas 75208, United States
  • Northwest Houston Clinical Research
    Tomball, Texas 77375, United States
  • Synexus Clinical Research US, Inc.
    Salt Lake City, Utah 84106, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Hampton Roads Center for Clinical Research
    Suffolk, Virginia 23434, United States
  • Universal Research Group, LLC
    Tacoma, Washington 98405, United States
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Peking University First Hospital
    Beijing, 100034, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, 233017, China
  • Cangzhou Central Hospital
    Cangzhou, 61017, China
  • China-Japan Union Hospital Of Jilin University
    Changchun, 130033, China
  • The First People's Hospital of Changde City
    Changde, 415003, China
  • The Second People's Hospital of Changzhou
    Changzhou, 213164, China
  • Affiliated Hospital of Chifeng University
    Chifeng, 24050, China
  • Chifeng Municipal Hospital
    Chifeng, 24099, China
  • Daqing People's Hospital
    Daqing, 163711, China
  • Foshan First People's Hospital
    Foshan, 528010, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • The Third Affiliated Hospital of Guangzhou Medical university
    Guangzhou, 510150, China
  • Heilongjiang Provincial Hospital
    Harbin, 150036, China
  • The First Affiliated Hospital Of University Of South China
    Hunan, 421001, China
  • Jinan Central Hospital
    Jinan, 250013, China
  • Hebei Petro China Central Hospital
    Langfang, 65099, China
  • Lishui Central Hospital
    Lishui, 323020, China
  • Luoyang Third People's Hospital
    Luoyang, 471002, China
  • The First affiliated Hospital of Nanyang Medical College
    Nanyang, 473024, China
  • Panjin Liaoyou Gem Flower Hospital
    Panjin, 124010, China
  • Huabei Petroleum Administration Bureau General Hospital
    Renqiu, 62550, China
  • Tianjin People's Hospital
    Tianjin, 300121, China
  • Tianjin Fourth Central Hospital
    Tianjin, 300143, China
  • Wenzhou People's Hospital
    Wenzhou, 325099, China
  • Xi'an Gaoxin Hospital
    Xi'an, 710075, China
  • Xianyang Hospital of Yan 'an University
    Xianyang, 712099, China
  • The Third Affiliatied Hospital of Xinxiang Medical University
    Xinxiang, 453000, China
  • Zaozhuang Municipal Hospital
    Zaozhuang, 277102, China
  • Hornicka nemocnice s poliklinikou Bilina s.r.o.
    Bílina, 418 01, Czechia
  • Medicus Services SRO
    Brandýs nad Labem, 250 01, Czechia

Showing the first 100 of 181 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Goldberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh A, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 Aug;274:32-45. doi: 10.1016/j.ahj.2024.05.002. Epub 2024 May 4. PubMed 38705341 ↗
  • Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Harada-Shiba M, Curcio DL, Neild A, Kling D, Hsieh A, Butters J, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Huo Y, Szarek M, Balinskaite V, Davidson MH; BROADWAY Investigators. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 3;393(1):51-61. doi: 10.1056/NEJMoa2415820. Epub 2025 May 7. PubMed 40337982 ↗
  • Davidson MH, Szarek M, Scheltens P, Vijverberg E, Hsieh A, Ditmarsch M, Kling D, Curcio D, Nicholls SJ, Ray KK, Cummings JL, Kastelein JJ. Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026 Jan;13(1):100394. doi: 10.1016/j.tjpad.2025.100394. Epub 2025 Oct 17. PubMed 41109840 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Sep 2024, 33 months.

Results were first posted in Sep 2025, 11 months after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 33 months is above that.

Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Dec 3, 2021
StartActual
Dec 15, 2021
Primary completionActual
Sep 26, 2024
CompletionActual
Sep 26, 2024
Results first posted
Sep 19, 2025
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05142722
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Dec 15, 2021
Primary completion
Sep 26, 2024
Completion
Sep 26, 2024
Results posted
Sep 19, 2025
Last update
Sep 19, 2025

Study contacts

Marc Ditmarsch
study director · NewAmsterdam Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion